Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > How Algernon Pharmaceuticals is aiming to use psychedelics

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Feb 18, 2021 6:07pm

156 Views

Post# 32605026

RE:How Algernon Pharmaceuticals is aiming to use psychedelics

UVPGuy wrote: Today, BNN Bloomberg posted an article on Algernon Pharmaceuticals (CSE: AGN | OTCQB: AGNPF | XFRA: AGW) and the use of psychedelics to aid stroke recovery. Pre-clinical testing of DMT has shown promise for stroke patients with Phase 1 human trials planned for 2021.

“You can still get neurogenesis and neuroplasticity without giving a person a psychedelic experience.” — Christopher Moreau, CEO, Algernon Pharmaceuticals Inc.

Read the article: https://www.bnnbloomberg.ca/how-algernon-pharmaceuticals-is-aiming-to-use-psychedelics-to-aid-stroke-recovery-1.1564727

Learn more about Algernon Pharmaceuticals: https://algernonpharmaceuticals.com/